標題: Titlebook: Clinical Trials In Parkinson‘s Disease; Santiago Perez-Lloret Book 2021 Springer Science+Business Media, LLC, part of Springer Nature 2021 [打印本頁] 作者: 畸齒矯正學 時間: 2025-3-21 18:21
書目名稱Clinical Trials In Parkinson‘s Disease影響因子(影響力)
書目名稱Clinical Trials In Parkinson‘s Disease影響因子(影響力)學科排名
書目名稱Clinical Trials In Parkinson‘s Disease網(wǎng)絡公開度
書目名稱Clinical Trials In Parkinson‘s Disease網(wǎng)絡公開度學科排名
書目名稱Clinical Trials In Parkinson‘s Disease被引頻次
書目名稱Clinical Trials In Parkinson‘s Disease被引頻次學科排名
書目名稱Clinical Trials In Parkinson‘s Disease年度引用
書目名稱Clinical Trials In Parkinson‘s Disease年度引用學科排名
書目名稱Clinical Trials In Parkinson‘s Disease讀者反饋
書目名稱Clinical Trials In Parkinson‘s Disease讀者反饋學科排名
作者: 正論 時間: 2025-3-21 20:29
Assessment of Nonmotor Symptoms in Rodent Models of Parkinson’s Disease (PD) neuropathology and to develop new therapeutic strategies. The toxin-based rodent models of PD offer a valuable tool as they allow to mimic many of the features of the disease, particularly motor symptoms such as akinesia and bradykinesia. Interestingly, PD nonmotor symptoms, such as neuropsych作者: 小爭吵 時間: 2025-3-22 00:42
Genetic Models of Parkinson’s Disease The etiology of idiopathic PD, which represents most of the cases, is still unclear but seems to be multifactorial, associating environmental and/or genetic factors. The major limitation of “classical” toxin-based animal models of PD?is that they?do not replicate some characterizing features of the作者: 多嘴 時間: 2025-3-22 08:14 作者: 昏睡中 時間: 2025-3-22 10:07 作者: Inscrutable 時間: 2025-3-22 15:10
Clinical Trials for Disease-Modifying Agents in Parkinson’s Diseaseor this. PD is clinically and pathophysiologically heterogeneous and has relatively insidious and protracted progression. Symptomatic therapies confound measurement of the disease as well. With this complexity comes the challenge of identifying optimal study design and outcome measures for clinical 作者: Inscrutable 時間: 2025-3-22 19:05
Value and Methods of Pharmacovigilance in the Monitoring of Drug Safety in Parkinson’s Diseases a key role in evaluating drug safety and efficacy under real-world conditions of use following market authorization. Pharmacovigilance focuses mainly on adverse drug reactions (ADRs), which are unintended adverse medical events caused by an approved drug used at normal human doses for the prophyla作者: inscribe 時間: 2025-3-22 22:11 作者: Prognosis 時間: 2025-3-23 04:52 作者: Glutinous 時間: 2025-3-23 05:51 作者: BURSA 時間: 2025-3-23 10:17
Clinical Trials for Orthostatic Hypotension in Parkinson’s Disease and Other Synucleinopathiesies. Patients with Parkinson disease and nOH suffer from more hospitalizations, emergency room visits, more telephone calls and e-mails to providers, and have a significantly shorter survival compared to patients with Parkinson disease and no nOH. Overall, health-related costs in patients with Parki作者: 新鮮 時間: 2025-3-23 17:12 作者: Longitude 時間: 2025-3-23 19:53 作者: forestry 時間: 2025-3-24 01:04
A Review of Randomized Phase III Pharmacological Clinical Trials for Motor Symptoms in Parkinson’s D作者: 不可接觸 時間: 2025-3-24 03:23 作者: 饑荒 時間: 2025-3-24 08:01 作者: Antagonism 時間: 2025-3-24 11:08
Clinical Trials for Motor Complications in Parkinson’s Disease for the treatment of motor complications has focused mostly in the symptomatic treatment of established motor complications, namely, for the reduction of daily off-time duration, peak-dose dyskinesia, followed by the acute rescue of an off-time. A significant number of clinical trials has been cond作者: moribund 時間: 2025-3-24 18:08 作者: 大看臺 時間: 2025-3-24 19:08 作者: construct 時間: 2025-3-25 01:33
Clinical Trials on Management of Pain in Parkinson’s Diseaseive to these features..In this book chapter, we discuss and outline the evaluation of PD-related pain, review PD general and specific pain assessment tools, and discuss relevant clinical trials addressing treatment of pain in PD.作者: CRAFT 時間: 2025-3-25 05:24 作者: intertwine 時間: 2025-3-25 11:14 作者: 檢查 時間: 2025-3-25 12:31
A Satellite for the Galileo Mission for the treatment of motor complications has focused mostly in the symptomatic treatment of established motor complications, namely, for the reduction of daily off-time duration, peak-dose dyskinesia, followed by the acute rescue of an off-time. A significant number of clinical trials has been cond作者: 名字 時間: 2025-3-25 16:43
,Evolution of the Term “Satellite DNA”,scussed. Special emphasis is placed on considerations for clinical trials testing immunotherapies. Much progress has been made in identifying who is at risk of PD and characterizing the prodromal PD phase, and clinical trials to prevent PD are on the horizon. Important aspects of clinical trial desi作者: 一夫一妻制 時間: 2025-3-25 21:28
The Genomics of Plant Satellite DNA,nic health records or claims data representing active surveillance..Pharmacovigilance has contributed substantially to our knowledge of the safety of antiparkinsonian drugs. Though patients on dopamine agonists and/or L-DOPA usually develop diurnal somnolence or impulse-control disorders, because th作者: JAMB 時間: 2025-3-26 03:17 作者: gratify 時間: 2025-3-26 07:44 作者: Inflammation 時間: 2025-3-26 11:17 作者: 耐寒 時間: 2025-3-26 13:59 作者: 梯田 時間: 2025-3-26 18:04 作者: Collision 時間: 2025-3-26 23:40 作者: 我還要背著他 時間: 2025-3-27 03:26 作者: Recessive 時間: 2025-3-27 07:33
Clinical Trials for Erectile Dysfunction in Parkinson’s Diseaseents of ED in PD remain scarce, and existing studies were limited by small sample size and open-label methodology. Therefore, well-designed double-blind RCTs are required to further understand the efficacy and adverse effect profiles of these treatments in PD.作者: 暫時休息 時間: 2025-3-27 13:26 作者: invade 時間: 2025-3-27 16:34 作者: commune 時間: 2025-3-27 19:08 作者: 野蠻 時間: 2025-3-27 22:46
B. D. Tapley,A. R. Neto,B. E. Schutzutic approaches. This chapter will discuss the terminology and definition of depression, anxiety, apathy, and fatigue in PD, their differentiation from other PD- and non–PD-related symptoms, subtyping, physiological markers, as well as considerations related to the optimal outcome measures and design of clinical trials.作者: GLADE 時間: 2025-3-28 03:14
https://doi.org/10.1007/978-981-10-3713-9tools to assess subjective and objective outcome measures, and the pitfalls and considerations pertaining each of these methods. Clinical trials will be reviewed to identify strengths and weaknesses, and lastly, a series of recommendations will be outlined for the design of clinical trials for constipation in Parkinson’s disease.作者: 強制令 時間: 2025-3-28 07:23
Assessment of Nonmotor Symptoms in Rodent Models of Parkinson’s Diseaseimal models, although with some limitation..This chapter will provide an overview of the PD nonmotor symptoms in the most common toxin-based rodent models, highlighting their translational value for clinical investigations.作者: expunge 時間: 2025-3-28 10:51 作者: Cumulus 時間: 2025-3-28 15:55 作者: QUAIL 時間: 2025-3-28 22:49
Clinical Trials for Constipation in Parkinson’s Diseasetools to assess subjective and objective outcome measures, and the pitfalls and considerations pertaining each of these methods. Clinical trials will be reviewed to identify strengths and weaknesses, and lastly, a series of recommendations will be outlined for the design of clinical trials for constipation in Parkinson’s disease.作者: encyclopedia 時間: 2025-3-29 02:12
,Evolution of the Term “Satellite DNA”, disorders. Special focus is given to the different selection criteria for clinical trials with a recommendation of a five-step selection process. Furthermore, we describe the observational and interventional methods that can be used in the clinical trials focusing on PD gait disorders.作者: Sinus-Node 時間: 2025-3-29 04:20 作者: 慷慨不好 時間: 2025-3-29 09:32
Clinical Trials for Gait Disorders in Parkinson’s Disease disorders. Special focus is given to the different selection criteria for clinical trials with a recommendation of a five-step selection process. Furthermore, we describe the observational and interventional methods that can be used in the clinical trials focusing on PD gait disorders.作者: entice 時間: 2025-3-29 13:23 作者: 分發(fā) 時間: 2025-3-29 15:56 作者: vascular 時間: 2025-3-29 20:27
Neuromethodshttp://image.papertrans.cn/c/image/228259.jpg作者: FLOUR 時間: 2025-3-30 03:45
Frequency-Hopped Communications,pacta (SNc) projecting to the motor part of the striatum. Therefore, there is a long-standing interest in using animal models with severe nigrostriatal degeneration for experimental research. Pathophysiological and behavioral features of PD are best studied in mammalian species endowed with well-dev作者: ANTE 時間: 2025-3-30 06:49
VSAT and Mobile-Satellite Systems, (PD) neuropathology and to develop new therapeutic strategies. The toxin-based rodent models of PD offer a valuable tool as they allow to mimic many of the features of the disease, particularly motor symptoms such as akinesia and bradykinesia. Interestingly, PD nonmotor symptoms, such as neuropsych作者: 潔凈 時間: 2025-3-30 10:46 作者: nuclear-tests 時間: 2025-3-30 15:53
A Satellite for the Galileo Missionn’s disease (PD) and determine disability and reduction in quality of life. Currently, there are many options for the management of motor complications in PD namely oral pharmacological interventions for both motor fluctuations (various formulation of levodopa/carbidopa, catechol-O-methyl transferas作者: 火光在搖曳 時間: 2025-3-30 18:37
,Evolution of the Term “Satellite DNA”,ase progresses. Disorders of gait have a substantial effect on patient quality of life. Despite immense research efforts, gait disorders in PD and related complications remain challenging, especially concerning therapy. This chapter summarizes the current knowledge about the clinical picture of gait作者: Hormones 時間: 2025-3-30 22:23
,Evolution of the Term “Satellite DNA”,or this. PD is clinically and pathophysiologically heterogeneous and has relatively insidious and protracted progression. Symptomatic therapies confound measurement of the disease as well. With this complexity comes the challenge of identifying optimal study design and outcome measures for clinical 作者: capillaries 時間: 2025-3-31 02:41
The Genomics of Plant Satellite DNA,s a key role in evaluating drug safety and efficacy under real-world conditions of use following market authorization. Pharmacovigilance focuses mainly on adverse drug reactions (ADRs), which are unintended adverse medical events caused by an approved drug used at normal human doses for the prophyla作者: interrogate 時間: 2025-3-31 07:30
B. D. Tapley,A. R. Neto,B. E. Schutznctioning of patients. Despite their clinical relevance, only limited evidence is available regarding treatment interventions for these disorders, and properly designed trials with depression, anxiety, apathy, and fatigue as primary outcome measures have been scarce to this date. All of these disord作者: Friction 時間: 2025-3-31 10:01 作者: SLING 時間: 2025-3-31 15:49 作者: FOR 時間: 2025-3-31 20:04
